PL2807165T3 - Pochodne pirymido[4,5-b]indolu i ich zastosowanie do namnażania hematopoetycznych komórek macierzystych - Google Patents

Pochodne pirymido[4,5-b]indolu i ich zastosowanie do namnażania hematopoetycznych komórek macierzystych

Info

Publication number
PL2807165T3
PL2807165T3 PL13740815T PL13740815T PL2807165T3 PL 2807165 T3 PL2807165 T3 PL 2807165T3 PL 13740815 T PL13740815 T PL 13740815T PL 13740815 T PL13740815 T PL 13740815T PL 2807165 T3 PL2807165 T3 PL 2807165T3
Authority
PL
Poland
Prior art keywords
expensation
pirimido
indole
derivatives
stem cells
Prior art date
Application number
PL13740815T
Other languages
English (en)
Inventor
Guy Sauvageau
Yves Gareau
Réjean RUEL
Stéphane GINGRAS
Iman FARES
Original Assignee
Université de Montréal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48872865&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2807165(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Université de Montréal filed Critical Université de Montréal
Publication of PL2807165T3 publication Critical patent/PL2807165T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL13740815T 2012-01-27 2013-01-25 Pochodne pirymido[4,5-b]indolu i ich zastosowanie do namnażania hematopoetycznych komórek macierzystych PL2807165T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261591521P 2012-01-27 2012-01-27
EP13740815.9A EP2807165B1 (en) 2012-01-27 2013-01-25 Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells
PCT/CA2013/050052 WO2013110198A1 (en) 2012-01-27 2013-01-25 Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells

Publications (1)

Publication Number Publication Date
PL2807165T3 true PL2807165T3 (pl) 2019-09-30

Family

ID=48872865

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13740815T PL2807165T3 (pl) 2012-01-27 2013-01-25 Pochodne pirymido[4,5-b]indolu i ich zastosowanie do namnażania hematopoetycznych komórek macierzystych

Country Status (27)

Country Link
US (3) US9409906B2 (pl)
EP (1) EP2807165B1 (pl)
JP (1) JP6250556B2 (pl)
KR (1) KR102098122B1 (pl)
CN (1) CN104144931B (pl)
AU (1) AU2013212457B2 (pl)
BR (1) BR112014018524B1 (pl)
CA (1) CA2862140C (pl)
CY (1) CY1121799T1 (pl)
DK (1) DK2807165T3 (pl)
ES (1) ES2733946T3 (pl)
FR (1) FR26C1003I1 (pl)
HR (1) HRP20191189T1 (pl)
HU (1) HUE044070T4 (pl)
IL (1) IL233587B (pl)
LT (2) LT2807165T (pl)
NL (1) NL301363I2 (pl)
NO (1) NO2026005I1 (pl)
NZ (1) NZ627188A (pl)
PL (1) PL2807165T3 (pl)
PT (1) PT2807165T (pl)
RS (1) RS59002B1 (pl)
SG (1) SG11201404241SA (pl)
SI (1) SI2807165T1 (pl)
SM (1) SMT201900360T1 (pl)
TR (1) TR201909582T4 (pl)
WO (1) WO2013110198A1 (pl)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2807165T3 (pl) 2012-01-27 2019-09-30 Université de Montréal Pochodne pirymido[4,5-b]indolu i ich zastosowanie do namnażania hematopoetycznych komórek macierzystych
EP2970312B1 (en) 2013-03-11 2017-11-15 The Regents of The University of Michigan Bet bromodomain inhibitors and therapeutic methods using the same
US9757378B2 (en) 2013-05-17 2017-09-12 Universite De Montreal Methods to modulate acute myeloid leukemia stem/progenitor cell expansion and/or differentiation
US9580430B2 (en) 2014-02-28 2017-02-28 The Regents Of The University Of Michigan 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors
US10647718B2 (en) 2014-04-22 2020-05-12 Universitéde Montréal Compounds and use thereof in the expansion of hematopoietic stem cells and/or hematopoietic progenitor cells
PL3194602T3 (pl) 2014-09-18 2020-07-27 Université de Montréal Związki i sposoby dla wzmocnienia przeniesienia wirusowego genu do ludzkich komórek krwiotwórczych
JP2018502115A (ja) * 2014-12-31 2018-01-25 アントフロゲネシス コーポレーション ナチュラルキラー細胞及びその使用
JP6734283B2 (ja) 2015-01-21 2020-08-05 フレッド ハッチンソン キャンサー リサーチ センター 遺伝子治療用ポイントオブケア及び／又はポータブルプラットフォーム
WO2016191879A1 (en) 2015-06-05 2016-12-08 Héma-Québec Methods for culturing and/or differentiating hematopoietic stem cells into progenitors and uses thereof
WO2016210292A1 (en) 2015-06-25 2016-12-29 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
CN105316293A (zh) * 2015-09-23 2016-02-10 广东颐养抗衰老研究院 一种体外获得造血干/祖细胞的方法
BR112018007538A2 (pt) * 2015-10-15 2018-10-23 Celularity Inc células exterminadoras naturais e células ilc3 e usos das mesmas
SG11201805217XA (en) * 2015-12-28 2018-07-30 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies
WO2017161001A1 (en) 2016-03-15 2017-09-21 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
SG11201809858RA (en) * 2016-05-07 2018-12-28 Celularity Inc Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells
AU2017325511B2 (en) * 2016-08-18 2021-12-09 National University Of Singapore Substituted azole derivatives for generation, proliferation and differentiation of hematopoietic stem and progenitor cells
US20190203230A1 (en) 2016-09-28 2019-07-04 Novartis Ag Porous membrane-based macromolecule delivery system
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
KR102832035B1 (ko) 2017-09-29 2025-07-09 인텔리아 테라퓨틱스, 인크. 지질 나노파티클을 이용한 mRNA 전달의 체외 방법
JP7499698B2 (ja) 2017-11-03 2024-06-14 ウニヴェルシテ ド モントリオール 化合物及び幹細胞及び／又は前駆細胞の増殖におけるその使用
WO2019136159A1 (en) * 2018-01-03 2019-07-11 Magenta Therapeutics Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders
US12011460B2 (en) * 2018-02-20 2024-06-18 Universite De Montreal Expansion of NK and DC cells in vivo mediating immune response
FI3873903T3 (fi) * 2018-10-31 2024-03-26 Gilead Sciences Inc Substituoituja 6-azabentsiimidatsoliyhdisteitä HPK1-inhibiittoreina
KR102329235B1 (ko) 2018-11-21 2021-11-22 한국화학연구원 Irak4 저해제로서 신규의 삼중고리 화합물
US11697799B2 (en) 2019-04-15 2023-07-11 Ossium Health, Inc. System and method for extraction and cryopreservation of bone marrow
CA3164153A1 (en) * 2019-12-18 2021-06-24 Universite De Montreal Modulators of cullin 3 adaptor kbtbd4 as anti-cancer compounds
WO2021123920A1 (en) 2019-12-18 2021-06-24 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies
CA3165443A1 (en) * 2019-12-26 2021-07-01 Sumitomo Pharma Co., Ltd. Method for culturing hematopoietic stem cells
WO2021224633A1 (en) 2020-05-06 2021-11-11 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
WO2021256977A1 (en) * 2020-06-15 2021-12-23 Subramaniam Agatheeswaran Novel methods and compounds for protein degradation
US20230256029A1 (en) * 2020-06-25 2023-08-17 Angiocrine Bioscience, Inc. Endothelial cells for mitigation of chemotherapy-induced toxicity
WO2022020210A1 (en) 2020-07-18 2022-01-27 Ossium Health, Inc. Permeation of whole vertebral bodies with a cryoprotectant using vacuum assisted diffusion
CN116583594B (zh) 2020-10-14 2025-05-23 奥瑟姆健康公司 用于骨髓的提取和低温保藏的系统和方法
CN117279650A (zh) 2020-12-18 2023-12-22 奥瑟姆健康公司 细胞治疗方法
TW202309044A (zh) * 2021-04-26 2023-03-01 日商住友製藥股份有限公司 氧呯衍生物
WO2022232839A1 (en) 2021-04-30 2022-11-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for improved production of primary cd34+ cells
EP4359527A2 (en) 2021-06-23 2024-05-01 Novartis AG Compositions and methods for the treatment of hemoglobinopathies
GB202111169D0 (en) 2021-08-03 2021-09-15 Adaptimmune Ltd Methods of T cell production
CN114736862B (zh) * 2022-05-18 2024-05-28 诺航生物技术研究院徐州有限公司 一种造血干细胞培养基和造血干细胞的体外扩增方法
CN117164593A (zh) * 2023-08-31 2023-12-05 贵州省天然产物研究中心 一种嘧啶并吲哚类化合物及其制备方法和应用、抗红白血病药物
US11945818B1 (en) 2023-09-06 2024-04-02 King Faisal University Pyrrolo[3,2-c]quinoline compounds as CK2 inhibitors
US11964981B1 (en) 2023-09-18 2024-04-23 King Faisal University Substituted pyrimido[4,5-b]indoles as CK2 inhibitors
CN117229284B (zh) * 2023-11-10 2024-02-06 上海泽德曼医药科技有限公司 三环稠杂环类化合物、其制备方法及其在医药上的应用
US12012414B1 (en) 2024-01-04 2024-06-18 King Faisal University Imidazo[1,5-a]pyrido[4,3-e]pyrimidines as CK2 inhibitors

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1262864A (en) * 1968-03-29 1972-02-09 Glaxo Lab Ltd Diazacarbazoles
JPH08502721A (ja) 1992-04-03 1996-03-26 ジ・アップジョン・カンパニー 医薬的に活性な二環式‐複素環アミン
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
ATE212993T1 (de) 1995-07-06 2002-02-15 Novartis Erfind Verwalt Gmbh Pyrolopyrimidine und verfahren zu ihrer herstellung
US5932728A (en) * 1997-01-08 1999-08-03 Pharmacia & Upjohn Company Pharmaceutically active tricyclic amines
AU1732900A (en) 1998-11-17 2000-06-05 Ligand Pharmaceuticals Incorporated Methods of treating thrombocytopenia
GC0000177A (en) 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics
EP1175421A1 (en) * 1999-04-30 2002-01-30 Neurogen Corporation 9H-PYRIMIDO[4,5-b]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS
EP1189609A4 (en) 1999-05-03 2002-10-30 Smithkline Beecham Corp CXCR-4 RECEPTOR ANTAGONISTS AND THROMBOPOIETIN MIMETIKA
ES2256038T3 (es) 1999-09-10 2006-07-16 Smithkline Beecham Corporation Mimeticos de trombopoyetina.
DE60032783T2 (de) 1999-09-24 2007-12-06 Smithkline Beecham Corp. Thrombopoietinmimetika
WO2001034585A1 (en) 1999-11-05 2001-05-17 Smithkline Beecham Corporation Semicarbazone derivatives and their use as thrombopoietin mimetics
EP1244446B1 (en) 1999-12-06 2006-11-02 SmithKline Beecham Corporation Thrombopoietin mimetics
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
EP1349613A4 (en) 2000-12-19 2005-09-21 Smithkline Beecham Corp MIMETICS OF THROMBOPOIETINE
EP1370252A4 (en) 2001-03-01 2006-04-05 Smithkline Beecham Corp Thrombopoietin mimetics
WO2002089746A2 (en) 2001-05-09 2002-11-14 The University Of Louisville Research Foundation, Inc. Hematopoietic stem cell chimerism to treat autoimmune disease
CA2464934A1 (en) 2001-10-31 2003-05-08 Bayer Healthcare Ag Pyrimido [4,5-b] indole derivatives
US7414040B2 (en) 2002-06-06 2008-08-19 Smithkline Beecham Corporation Thrombopoietin mimetics
EP1581527A4 (en) 2002-12-13 2006-11-22 Smithkline Beecham Corp MIMETICS OF THROMBOPOIETINE
AU2003300522A1 (en) 2002-12-27 2004-07-22 Bayer Healthcare Ag 4-phenyl-pyrimido (4,5-b) indole derivatives
JP2006525013A (ja) 2003-05-02 2006-11-09 インセプション バイオサイエンス インコーポレイティッド 血液幹細胞の数の増幅のための装置および方法
ES2344007T3 (es) 2003-10-14 2010-08-16 The Arizona Board Of Regents On Behalf Of The University Of Arizona Inhibidores proteina quinasa.
JP2008539277A (ja) * 2005-04-28 2008-11-13 スーパージェン， インコーポレイテッド プロテインキナーゼインヒビター
RU2008105071A (ru) 2005-07-14 2009-08-20 Айрм Ллк (Bm) Соединения и композиции в качестве миметиков tro
DE602005010421D1 (de) * 2005-08-05 2008-11-27 Hybrigenics Sa Neue Cysteine Protease Hemmers und ihre therapeutische Anwendungen
EP1915341A2 (en) 2005-08-15 2008-04-30 Irm, Llc Compounds and compositions as tpo mimetics
JPWO2007145227A1 (ja) 2006-06-14 2009-11-05 中外製薬株式会社 造血幹細胞増加促進剤
JP2008050355A (ja) * 2006-08-21 2008-03-06 Eisai R & D Management Co Ltd 造血幹細胞を増殖、分化および／または循環系内に動員させる医薬組成物および方法
WO2008028645A1 (en) 2006-09-05 2008-03-13 Aplagen Gmbh Peptides binding the tpo receptor
WO2008055233A1 (en) 2006-10-31 2008-05-08 Supergen, Inc. Protein kinase inhibitors
EP2094839B1 (en) 2006-12-08 2020-02-05 University of Rochester Expansion of hematopoietic stem cells
EP2121692B1 (en) 2006-12-22 2013-04-10 Incyte Corporation Substituted heterocycles as janus kinase inhibitors
WO2008137641A2 (en) 2007-05-04 2008-11-13 Whitehead Institute For Biomedical Research Ex vivo expansion of human hematopoietic stem cells
WO2009004329A1 (en) * 2007-07-02 2009-01-08 Cancer Research Technology Limited 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors
US7982035B2 (en) 2007-08-27 2011-07-19 Duquesne University Of The Holy Spirit Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
JP2010193879A (ja) * 2009-01-27 2010-09-09 Jms Co Ltd 臍帯血造血幹細胞の増殖制御方法およびその用途
WO2011056739A1 (en) 2009-11-03 2011-05-12 Glaxosmithkline Llc Compounds and methods
TWI527818B (zh) 2011-03-15 2016-04-01 特留斯治療學有限公司 三環旋轉酶抑制劑
PL2807165T3 (pl) 2012-01-27 2019-09-30 Université de Montréal Pochodne pirymido[4,5-b]indolu i ich zastosowanie do namnażania hematopoetycznych komórek macierzystych

Also Published As

Publication number Publication date
BR112014018524B1 (pt) 2023-03-28
CY1121799T1 (el) 2020-07-31
SI2807165T1 (sl) 2019-08-30
CA2862140C (en) 2020-04-21
CN104144931B (zh) 2018-04-10
CN104144931A (zh) 2014-11-12
NO2026005I1 (no) 2026-01-21
HUE044070T2 (hu) 2019-09-30
US20170334904A1 (en) 2017-11-23
RS59002B1 (sr) 2019-08-30
BR112014018524A2 (pt) 2021-06-08
DK2807165T3 (da) 2019-07-15
US10336747B2 (en) 2019-07-02
NZ627188A (en) 2015-12-24
EP2807165A1 (en) 2014-12-03
JP6250556B2 (ja) 2017-12-20
IL233587B (en) 2019-11-28
WO2013110198A1 (en) 2013-08-01
HRP20191189T1 (hr) 2019-10-04
IL233587A0 (en) 2014-08-31
LTPA2026503I1 (pl) 2026-02-10
TR201909582T4 (tr) 2019-07-22
HUE044070T4 (hu) 2019-12-30
SG11201404241SA (en) 2014-08-28
ES2733946T3 (es) 2019-12-03
CA2862140A1 (en) 2013-08-01
AU2013212457B2 (en) 2017-02-16
NL301363I2 (nl) 2026-02-19
KR102098122B1 (ko) 2020-04-07
BR112014018524A8 (pt) 2017-07-11
SMT201900360T1 (it) 2019-07-11
EP2807165B1 (en) 2019-05-15
JP2015504902A (ja) 2015-02-16
US20160222017A1 (en) 2016-08-04
KR20140121454A (ko) 2014-10-15
FR26C1003I1 (fr) 2026-03-06
EP2807165A4 (en) 2015-08-26
LT2807165T (lt) 2019-07-25
HK1203945A1 (en) 2015-11-06
PT2807165T (pt) 2019-07-12
AU2013212457A1 (en) 2014-09-18
US20150011543A1 (en) 2015-01-08
US9409906B2 (en) 2016-08-09

Similar Documents

Publication Publication Date Title
PL2807165T3 (pl) Pochodne pirymido[4,5-b]indolu i ich zastosowanie do namnażania hematopoetycznych komórek macierzystych
ZA201507874B (en) 2-aminopyrido[4,3-d]pyrimidin-5-one derivatives and their use as wee-1 inhibitors
DK2882850T3 (da) System for preparation of adipose-derived stem cells
HUE046216T2 (hu) 1H-pirazolo [3,4-b]piridin-származékok és terápiás alkalmazásuk
HUE053688T2 (hu) Biciklusos heterociklusos vegyületek és ezek terápiában történõ alkalmazása
IL231903A0 (en) 5,7-substituted-imidazo[1,2-c]pyrimidines
CO6801742A2 (es) Derivados de ácido 3-fenilpropiónico ramificados y su uso
CO7000778A2 (es) Derivados de pirazolopiridina, su procedimiento de preparación y su uso terapéutico
HRP20181310T1 (hr) Novi heterociklički derivati i njihova uporaba
CO6990717A2 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
FR2989710B1 (fr) Protection contre le soleil
IL247798B (en) Expansion of mature stem cells in vitro
UY34018A (es) Derivados glucósidos y usos de los mismos
IL241808B (en) History of n-(2, 3-dihydro-1h-pyrrolo [3,2-b] pyridine-5-yl)-4-quinazolinamine and n-(2, 3-dihydro-1h-indole-5-yl} – 4-quinazolinamine as perk inhibitors
EP2963013A4 (en) INDOLE AND AZAINDOLE DERIVATIVES HAVING AMPK ACTIVATION ACTIVITY EACH
PL2831110T3 (pl) Terapia anty-EMP2 zmniejsza ilość rakowych komórek macierzystych
IL230655A0 (en) N-hetero-ring-substituted amide derivatives, compositions comprising the same and uses thereof
DE112013002488T8 (de) Vesikuläre Formulierungen, Kits und Verwendungen
PL395184A1 (pl) Nowe pochodne benzimidazolu, sposób wytwarzania i zastosowanie pochodnych benzimidazolu
TH1401007032A (th) การสังเคราะห์ไพร์โรโล [2,3-b] ไพริดีน
PL390435A1 (pl) Nowe pochodne 1,3,5-triazyny oraz sposób ich otrzymywania
TH1401003816A (th) องค์ประกอบ, การสังเคราะห์, และ วิธีการของการใช้อนุพันธ์ฟีนิลไซโคลอัลคิลเมทธิลเอมีน